Icecure Medical
IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 syst… Read more
Icecure Medical (ICCM) - Net Assets
Latest net assets as of September 2025: $9.31 Million USD
Based on the latest financial reports, Icecure Medical (ICCM) has net assets worth $9.31 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.08 Million) and total liabilities ($5.77 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.31 Million |
| % of Total Assets | 61.72% |
| Annual Growth Rate | 14.12% |
| 5-Year Change | 50.58% |
| 10-Year Change | 79.24% |
| Growth Volatility | 169.5 |
Icecure Medical - Net Assets Trend (2014–2024)
This chart illustrates how Icecure Medical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Icecure Medical (2014–2024)
The table below shows the annual net assets of Icecure Medical from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.90 Million | -43.26% |
| 2023-12-31 | $12.16 Million | -52.16% |
| 2022-12-31 | $25.42 Million | -5.70% |
| 2021-12-31 | $26.96 Million | +488.21% |
| 2020-12-31 | $4.58 Million | +74.51% |
| 2019-12-31 | $2.63 Million | -22.00% |
| 2018-12-31 | $3.37 Million | +1410.37% |
| 2017-12-31 | $-256.93K | -112.22% |
| 2016-12-31 | $2.10 Million | -45.38% |
| 2015-12-31 | $3.85 Million | +109.04% |
| 2014-12-31 | $1.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Icecure Medical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7943246270.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $112.28 Million | 1627.01% |
| Total Equity | $6.90 Million | 100.00% |
Icecure Medical Competitors by Market Cap
The table below lists competitors of Icecure Medical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Synergy Green Industries Limited
NSE:SGIL
|
$27.33 Million |
|
Jasper Therapeutics Inc
NASDAQ:JSPR
|
$27.33 Million |
|
Poznanska Korporacja Budowlana Pekabex SA
WAR:PBX
|
$27.34 Million |
|
SRV Group plc
HE:SRV1V
|
$27.36 Million |
|
Everyday People Financial Corp.
V:EPF
|
$27.31 Million |
|
Excellon Resources Inc
PINK:EXNRF
|
$27.31 Million |
|
Ecos India Mobility & Hospitality Ltd
NSE:ECOSMOBLTY
|
$27.30 Million |
|
Xtant Medical Holdings Inc
NYSE MKT:XTNT
|
$27.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Icecure Medical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,163,000 to 6,901,000, a change of -5,262,000 (-43.3%).
- Net loss of 15,318,000 reduced equity.
- New share issuances of 9,187,000 increased equity.
- Other factors increased equity by 869,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-15.32 Million | -221.97% |
| Share Issuances | $9.19 Million | +133.13% |
| Other Changes | $869.00K | +12.59% |
| Total Change | $- | -43.26% |
Book Value vs Market Value Analysis
This analysis compares Icecure Medical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.90x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.46x to 4.90x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $1.44 | $0.67 | x |
| 2015-12-31 | $0.84 | $0.67 | x |
| 2016-12-31 | $0.40 | $0.67 | x |
| 2017-12-31 | $-0.04 | $0.67 | x |
| 2018-12-31 | $0.29 | $0.67 | x |
| 2019-12-31 | $0.19 | $0.67 | x |
| 2020-12-31 | $0.27 | $0.67 | x |
| 2021-12-31 | $0.94 | $0.67 | x |
| 2022-12-31 | $0.69 | $0.67 | x |
| 2023-12-31 | $0.27 | $0.67 | x |
| 2024-12-31 | $0.14 | $0.67 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Icecure Medical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -221.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -465.45%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.82x
- Recent ROE (-221.97%) is below the historical average (-122.44%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -255.94% | -441.14% | 0.32x | 1.79x | $-4.90 Million |
| 2015 | -97.45% | -491.81% | 0.15x | 1.31x | $-4.14 Million |
| 2016 | -155.51% | -522.82% | 0.19x | 1.58x | $-3.48 Million |
| 2017 | 0.00% | -417.15% | 0.36x | 0.00x | $-2.85 Million |
| 2018 | -104.97% | -329.70% | 0.20x | 1.56x | $-3.87 Million |
| 2019 | -181.26% | -287.18% | 0.23x | 2.79x | $-5.02 Million |
| 2020 | -104.23% | -116.96% | 0.40x | 2.26x | $-5.24 Million |
| 2021 | -37.34% | -243.26% | 0.13x | 1.20x | $-12.76 Million |
| 2022 | -67.72% | -558.09% | 0.10x | 1.19x | $-19.76 Million |
| 2023 | -120.46% | -453.76% | 0.20x | 1.35x | $-15.87 Million |
| 2024 | -221.97% | -465.45% | 0.26x | 1.82x | $-16.01 Million |
Industry Comparison
This section compares Icecure Medical's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Icecure Medical (ICCM) | $9.31 Million | -255.94% | 0.62x | $27.32 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |